Sign in to view content

High-dose Aflibercept Therapy in nAMD and DME Eyes With Suboptimal Response to Standard Dose of Anti-VEGF Therapy: A Retrospective Analysis

Jared S. Nielsen, MD, MBA

Video
Published 2020

Related

Long-term Experience With Intravitreal Anti-VEGF Treatment in Patients With nAMD: Analysis of IRIS® (Intelligent Research in Sight) Registry Database
Theodore Leng, MD, MS, FASRS
Annual Meeting Talks
2021
Treatment Burden and Vision Analysis of Anti-VEGF Therapies for the Treatment of Neovascular AMD
Rahul Komati, MD
Annual Meeting Talks
2020
12-Month Ocular Pharmacokinetic Study of EYP-1901 a Sustained-Release Intravitreal Formulation of the Tyrosine Kinase Inhibitor Vorolanib
Rishi P. Singh, MD
Annual Meeting Talks
2023

Category: Pharmacology

See more